Cell or Molecular Dysfunction

Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics

1 week ago talkbio0Tagged Acquisition, KRAS NP_004976.2:p.G12C, Myers Squibb, Neoplasms

Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C

Argenx Appoints Karen Massey as New CEO in Leadership Transition

3 weeks ago talkbio0Tagged Argenx, CEO, Infrequent, Karen Massey, Leadership, Tim Van Hauwermeiren, Transition Mutation

argenx; Karen Massey; CEO; Tim Van Hauwermeiren; leadership transition; rare diseases; Vyvgart

Coloplast announces changes to Executive Leadership Team

1 month ago talkbio0Tagged Administration occupational activities, Anthropological Culture, Changing, coloplast, ELT, Executive Leadership Team, Interventional Urology, Johns, Kevin Hardage, Leadership, Persons, Transition Mutation

Coloplast; Executive Leadership Team; ELT changes; Interventional Urology; People & Culture; Kevin Hardage; Tommy Johns; leadership transition; management changes

Enliven Therapeutics Announces New CEO

1 month ago talkbio0Tagged CEO, ELVN, Enliven Therapeutics, Leadership, Myeloid Leukemia, Chronic, Phase 3 trial, Richard Fair, Rick Fair, Transition Mutation

Enliven Therapeutics; ELVN; new CEO; Rick Fair; Richard Fair; Sam Kintz; leadership transition; Phase 3 trial; ELVN-001; chronic myeloid leukemia; CML; biotech; Nasdaq ELVN

GSK walks away from remaining IDEAYA programs, formally ending partnership

2 months ago talkbio0Tagged Collaboration termination, DNA Repair, drug development pipeline, Ideaya Biosciences, License Agreement, oncology partnership, Pol Theta, SmithKline Beecham, Synthetic Lethality, Werner helicase

GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline

UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance

2 months ago talkbio0Tagged AMT-130, antibody collaboration, AstraZeneca, biopharmaceutical partnerships, external control group, Feedback - system communication, gene therapy, Nerve Degeneration, Neurimmune, UniQure, United States Food and Drug Administration

UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships

Marengo’s invikafusp alfa shows promising monotherapy activity in PD-1 resistant gastrointestinal cancers

2 months ago talkbio0Tagged Alfa, Colorectal Carcinoma, fast-track designation, High tumor mutational burden, High-Frequency Microsatellite Instability, Immunotherapy, invikafusp, Malignant neoplasm of gastrointestinal tract, Marengo Therapeutics, PDCD1 gene, resistant tumors, United States Food and Drug Administration

Invikafusp alfa; Marengo Therapeutics; PD-1 resistant tumors; Gastrointestinal cancers; Colorectal cancer; TMB-H; MSI-H; Immunotherapy; ESMO 2025; FDA Fast Track designation

FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

3 months ago talkbio0Tagged Acute leukemia, Antibody-Drug Conjugates, Approved, black-box warning, Chromosomal translocation, differentiation syndrome, KMT2A gene, Leukemia, Myelocytic, Acute, Menin Inhibitor, oncology drug approval, Revuforj, revumenib, SmithKline Beecham, Syndax, United States Food and Drug Administration

Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval

Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders

3 months ago talkbio0Tagged Accuray, cell transformation, CEO, Change, Organizational, executive appointments, Leadership, med-tech, operational transformation, Steve La Neve, Suzanne Winter, Transition Mutation

Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

4 months ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning